Search
Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC
CEO Eamonn Hobbs describes the responses Syncromune is seeing in an early phase 1 prostate cancer study.
Apr 8, 2024
top of page
Search
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.
bottom of page